JPMorgan raised the firm’s price target on NeuroPace (NPCE) to $16 from $14 and keeps an Overweight rating on the shares. The company reported good Q1 results ahead of the Street, with gross margin and revenue topping estimates and operating expense coming in lower, the analyst tells investors in a research note. This was another strong quarter for NeuroPace, with healthy contribution from Project Care, record new prescribers, and sustained utilization across Level 4 centers, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace reports Q1 EPS (21c), consensus (24c)
- NeuroPace sees FY25 revenue $93M-$97M, consensus $93.68M
- NPCE Upcoming Earnings Report: What to Expect?
- NeuroPace’s Strong Market Position and Growth Potential Justify Buy Rating Amid Tariff Stability
- NeuroPace Expects Minimal Impact from Trade Tariffs